Donepezil for Alzheimer's disease?

Drug and Therapeutics Bulletin

Volumn 35, Issue 10, 1997, Pages 75-76

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ARICEPT EISAI; CHOLINESTERASE INHIBITOR; DONEPEZIL; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITION; CONSERVATIVE TREATMENT; DEMENTIA; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FATIGUE; HEALTH CARE COST; HUMAN; INSOMNIA; MUSCLE CRAMP; NAUSEA; QUALITY OF LIFE; SHORT SURVEY; VOMITING;

EID: 0030711104     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1997.351075     Document Type: Short Survey

References (17)

1. Writing Committee, Lancet conference 1996. The challenge of the dementias Lancet 1996; 347: 1303-7.
2. Gray A. The costs of Alzheimer's disease. Care of the Elderly 1996; 26: 2-3.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
4. Dewar D, McCulloch J. Abnormalities in non-cholinergic neurotransmitter systems in Alzheimer's disease. In: Burns A, Levy R (Eds). Dementia. London: Chapman and Hall, 1994
5. Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. BMJ 1984; 288: 961-4.
6. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2: 1457-9
7. Allen NHP, Burns A. The treatment of Alzheimer's disease. J Psychopharmacol 1995, 9: 43-56.
8. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E (Eds). Cholinergic basis for Alzheimer's therapy Boston: Birkhäuser, 1991.
9. Bryson HM, Benfield P Donepezil. Drugs Aging 1997, 10: 234-9
10. Donepezil. Summary of product characteristics, UK. Eisai, July 1997.
11. Rogers SL, Friedhoff LT and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease. Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
12. Rosen WG, Mohs RC, Davis KL A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141. 1356-64.
13. Stern RG, Mohs RC, Davidson M et al A longitudinal study of Alzheimer's Disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 151: 390-6.
14. Folstein MF, Folstein S, McHugh P. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
15. Corey-Bloom J, Galasko D, Thal LJ. Longitudinal changes in cognition. In: Bums A, Levy R (Eds). Dementia. London: Chapman and Hall, 1994.
16. Rogers SL, Perdomo C, Friedhoff LT. Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Eur Neuropsychopharmacol 1995, 5. 386-7 [abstract P-8-21].
17. Rogers SL, Doody R, Mohs R, Friedhoff LT E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial. Neurology 1996; 46: A217 [abstract].